Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …
display a superior advantage because the nasal mucosa is often the initial site of infection …
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Multiple vaccines have recently been developed, and almost all the countries are presently
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
D Lapuente, J Fuchs, J Willar, A Vieira Antão… - Nature …, 2021 - nature.com
Several effective SARS-CoV-2 vaccines are currently in use, but effective boosters are
needed to maintain or increase immunity due to waning responses and the emergence of …
needed to maintain or increase immunity due to waning responses and the emergence of …
SARS-CoV-2 Omicron BA. 1 and BA. 2 are attenuated in rhesus macaques as compared to Delta
Since the emergence of SARS-CoV-2, five different variants of concern (VOCs) have been
identified: Alpha, Beta, Gamma, Delta, and Omicron. Because of confounding factors in the …
identified: Alpha, Beta, Gamma, Delta, and Omicron. Because of confounding factors in the …
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet
there is limited data on the immune response induced by heterologous vaccination …
there is limited data on the immune response induced by heterologous vaccination …
Adenoviral vector-based vaccine platform for COVID-19: Current status
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the
21st century, claiming millions of lives and putting a huge burden on the global economy …
21st century, claiming millions of lives and putting a huge burden on the global economy …
COVID-19 vaccines: adenoviral vectors
C Jacob-Dolan, DH Barouch - Annual review of medicine, 2022 - annualreviews.org
The worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the unprecedented pace of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the unprecedented pace of …
[HTML][HTML] Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
V Mouro, A Fischer - Mucosal immunology, 2022 - Elsevier
The development and deployment of vaccines against COVID-19 demonstrated major
successes in providing immunity and preventing severe disease and death. Yet SARS-CoV …
successes in providing immunity and preventing severe disease and death. Yet SARS-CoV …
Intranasal vaccine: Factors to consider in research and development
H Xu, L Cai, S Hufnagel, Z Cui - International journal of pharmaceutics, 2021 - Elsevier
Most existing vaccines for human use are administered by needle-based injection.
Administering vaccines needle-free intranasally has numerous advantages over by needle …
Administering vaccines needle-free intranasally has numerous advantages over by needle …
[HTML][HTML] Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic
acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from …
acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from …